Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

[1]  M. Sadelain,et al.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  R. Thorpe,et al.  Safety of biologics, lessons learnt from TGN1412. , 2009, Current opinion in biotechnology.

[3]  S. Rosenberg,et al.  A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity1 , 2009, The Journal of Immunology.

[4]  M. Brenner,et al.  Immunotherapy of human cancers using gene modified T lymphocytes. , 2009, Current gene therapy.

[5]  D. Campana,et al.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[7]  T. Watts,et al.  Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges , 2009, Immunological reviews.

[8]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[9]  M. Caligiuri,et al.  A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab , 2009, Breast Cancer Research and Treatment.

[10]  S. Rosenberg,et al.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[12]  Jinjuan Wang,et al.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.

[13]  S. Webber,et al.  Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation. , 2008, Clinics in laboratory medicine.

[14]  Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. , 2008, Human gene therapy.

[15]  Houli Wang,et al.  The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. , 2008, The American journal of emergency medicine.

[16]  L. Ciuffreda,et al.  Journal of Translational Medicine BioMed Central Commentary Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines , 2004 .

[17]  Z. Eshhar.  The T-body approach: redirecting T cells with antibody specificity. , 2008, Handbook of experimental pharmacology.

[18]  S. Ménard,et al.  Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. , 2007, Cancer research.

[19]  G. Franklin,et al.  Systemic inflammation after trauma. , 2007, Injury.

[20]  C. Trautwein,et al.  The interleukin‐6 (IL6)–174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6 , 2007, International journal of immunogenetics.

[21]  Y. Yarden,et al.  SnapShot: EGFR Signaling Pathway , 2007, Cell.

[22]  K. Blackwell,et al.  Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2 , 2007, Journal of Translational Medicine.

[23]  M. Wadhwa,et al.  “Cytokine Storm” in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics , 2007, The Journal of Immunology.

[24]  D. Busch,et al.  Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer , 2007, Cancer Immunology, Immunotherapy.

[25]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[26]  M. Slovak,et al.  Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  C. Vachani.  Tumor lysis syndrome. , 2007, Oncology.

[28]  S. Rosenberg,et al.  Presentation of Tumor Antigens by Dendritic Cells Genetically Modified With Viral and Nonviral Vectors , 2006, Journal of immunotherapy.

[29]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[30]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[31]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[32]  W. Russell,et al.  The emergence of ErbB2 expression in cultured rat hepatocytes correlates with enhanced and diversified EGF-mediated signaling. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[33]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Jorma Isola,et al.  Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma , 2006, Journal of Molecular Medicine.

[35]  L. Miteva,et al.  Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility , 2006, Intensive Care Medicine.

[36]  S. Rosenberg,et al.  Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR , 2005, The Journal of Immunology.

[37]  C. Shriver,et al.  Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[39]  Terry L. Smith,et al.  Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  P. Darcy,et al.  Gene modification strategies to induce tumor immunity. , 2005, Immunity.

[42]  S. Ménard,et al.  Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.

[43]  C. Shapiro,et al.  A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies , 2004, Clinical Cancer Research.

[44]  D. Cope.  Tumor lysis syndrome. , 2004, Clinical journal of oncology nursing.

[45]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[46]  M. Glennie,et al.  Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4‐1BB), and their role in the generation of anti‐tumor immune responses , 2002, European journal of immunology.

[47]  M. Cheever,et al.  Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  E. Akalin,et al.  Gene polymorphisms and transplantation. , 2001, Current opinion in immunology.

[49]  K. Welsh,et al.  The role of cytokine polymorphisms in rejection after solid organ transplantation , 2001, Genes and Immunity.

[50]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[51]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[52]  J. Ross,et al.  The HER-2/neu Oncogene in Tumors of the Gastrointestinal Tract , 2001, Cancer investigation.

[53]  Y. Yarden,et al.  The basic biology of HER2. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  C. Sgro.  Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. , 1995, Toxicology.

[55]  L. Weiner,et al.  Phase I Trial of 2B1, a Bispecific Monoclonal Antibody Targeting c-erbB-2 and FcγRIII , 1995 .

[56]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  N. Lemoine,et al.  Expression of the c-erbB-3 protein in normal human adult and fetal tissues. , 1992, Oncogene.

[58]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[59]  T. Kameda,et al.  Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. , 1990, Cancer research.

[60]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[61]  C. Ferran,et al.  IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION: SYSTEMIC CYTOKINE RELEASE AND MODULATION BY CORTICOSTEROIDS , 1990, Transplantation.

[62]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[63]  S M Larson,et al.  Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.